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Background: High LDL-cholesterol (LDL-C) and glucose levels are risk factors for ischemic heart disease (IHD) in
middle-aged diabetic individuals; however, the risk among the elderly, especially the very elderly, is not well known.
The aim of this study was to identify factors that predict IHD and cerebrovascular attack (CVA) in the elderly and to
investigate their differences by age.
Methods: We performed a prospective cohort study (Japan Cholesterol and Diabetes Mellitus Study) with 5.5 years
of follow-up. A total of 4,014 patients with type 2 diabetes and without previous IHD or CVA (1,936 women; age
67.4 ± 9.5 years, median 70 years; <65 years old, n = 1,261; 65 to 74 years old, n = 1,731; and ≥ 75 years old,
n = 1,016) were recruited on a consecutive outpatient basis from 40 hospitals throughout Japan. Lipids, glucose,
and other factors related to IHD or CVA risk, such as blood pressure (BP), were investigated using the multivariate
Cox hazard model.
Results: One hundred fifty-three cases of IHD and 104 CVAs (7.8 and 5.7/1,000 people per year, respectively)
occurred over 5.5 years. Lower HDL-cholesterol (HDL-C) and female gender were correlated with IHD in patients
≥75 years old (hazard ratio (HR):0.629, P < 0.01 and 1.132, P < 0.05, respectively). In contrast, systolic BP (SBP), HbA1C,
LDL-C and non-HDL-C were correlated with IHD in subjects <65 years old (P < 0.05), and the LDL-C/HDL-C ratio was
correlated with IHD in all subjects. HDL-C was correlated with CVA in patients ≥75 years old (HR: 0.536, P < 0.01).
Kaplan-Meier estimator curves showed that IHD occurred more frequently in patients <65 years old in the highest
quartile of the LDL-C/HDL-C ratio. In patients ≥75 years old, IHD and CVA were both the most frequent among
those with the lowest HDL-C levels.
Conclusions: IHD and CVA in late elderly diabetic patients were predicted by HDL-C. LDL-C, HbA1C, SBP and
non-HDL-C are risk factors for IHD in the non-elderly. The LDL-C/HDL-C ratio may represent the effects of both
LDL-C and HDL-C. These age-dependent differences in risk are important for developing individualized strategies to
prevent atherosclerotic disease.
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Type 2 diabetes mellitus, dyslipidemia and aging are in-
dependent risk factors for cardiovascular diseases, such
as ischemic heart disease (IHD). Within diabetic indivi-
duals, lipids, especially LDL-cholesterol (LDL-C), blood
pressure (BP), and diabetic control are risk factors for
IHD [1-4]. For example, the United Kingdom Prospect-
ive Diabetes Study (UKPDS) showed the importance of
BP, lipids, and diabetic control in the prevention of IHD
in newly diagnosed diabetic individuals(mean age 53 years,
range 25–65 years), and subsequent studies have con-
firmed these findings [1,2]. However, the risk factors for
IHD or cerebrovascular attack (CVA) in elderly diabetic
individuals (older than 65 years), particularly in late elderly
diabetic individuals (older than 75 years), have not been
identified.
In Western countries, the evidence suggests that mid-
dle-aged diabetic individuals have an IHD risk similar
to that of non-diabetic patients who have experienced a
myocardial infarction, and the guidelines for diabetes
treatment recommend that the LDL-C level should be
less than 100 mg/dl, which is similar to the recommen-
dation for the secondary prevention of myocardial in-
farction [5,6]. However, it is unknown whether the same
risk exists for elderly diabetic individuals. Additionally,
many guidelines recommend strict control of LDL-C levels
to prevent atherothrombotic diseases, especially in diabe-
tic patients, yet recommend the same HDL-cholesterol
(HDL-C; 40 mg/dl) and triglyceride (TG; 150 mg/dl) levels
as for non-diabetic individuals [5-7]. There are few reports
on the absolute risk conferred by HDL-C and TG in
elderly diabetic patients.
Additionally, diabetes can either develop in the elderly
or continue through old age after an earlier onset. Even
in elderly individuals without diabetes, postprandial hy-
perglycemia occurs because of a delay in insulin secre-
tion in response to feeding and may contribute to an
increase in the number of elderly diabetic patients [8].
The International Diabetes Federation (IDF) reports that
the number of diabetic patients increased from 30 mil-
lion in 1987 to 246 million in 2007 (7% of adults) and
speculates that it will increase to 380 million by 2027
[9]. In Japan, 30% of diabetic individuals were elderly in
1997 (13% of the elderly suffered from diabetes mellitus),
which increased to 40% in 2007 (17% of the elderly).
Furthermore, individuals older than 75 (13 million) com-
prise over 10% of the total population. However, no
large-scale investigations have focused on type 2 diabetes
mellitus in the elderly, especially in the late elderly, or
those older than 75 [10]. Thus, evaluating the metabolic
predictors of atherosclerotic diseases, such as IHD and
CVA, in elderly diabetic individuals is important. For
these reasons, we organized the Japan Cholesterol and
Diabetes Mellitus Study (JCDM) to evaluate which factorscan predict IHD or CVA in diabetic patients, includ-
ing the elderly. Our elderly sample population inclu-
ded 1,016 late elderly, who were older than 75 and
performed independent daily life activities at outpatient
clinics [11].Materials and methods
Subjects
The JCDM is a prospective, cohort study that consists
of 4,014 Japanese diabetic individuals from 40 hospitals
throughout Japan who were recruited on a consecutive
outpatient basis between September 2004 and March
2005 (1,936 women; mean age 67.4 ± 9.5 years, median
age 70 years; Figure 1) [11]. The JCDM protocol, which
is in accordance with the provisions of the Declaration
of Helsinki, received ethical approval from the institu-
tional review boards of all the participating institutes.
Written informed consent was obtained from all pa-
tients. The criteria from the American Diabetes Associ-
ation for type 2 diabetes mellitus diagnosis were used
[6]. Patients with previous IHD (myocardial infarction,
unstable angina pectoris, angioplasty, or bypass grafting)
or CVA (recent stroke with admission within the past
24 months) were excluded, as were patients whose med-
ical records concerning plasma lipids (TG, HDL-C and
total cholesterol or LDL-C) were not provided. The other
exclusion criteria were a history or complication of serious
heart disease (e.g., severe arrhythmia, heart failure, cardio-
myopathy, valvular disease, or congenital disease), serious
hepatic or renal disease with admission within the past
24 months, malignant disease, intention to undergo sur-
gery, any illness with a poor prognosis of less than one
year, and judgment by the physician in charge that the pa-
tient was not suitable for the study.
At 24 months (2007), 92.3% of the enrolled patients
were followed up, and 84.1% were followed up at
66 months (2010). Patients were divided into groups
based on age at registration: younger than 65 (non-
elderly, n = 1,267), 65 to 74 years old (early elderly,
n = 1,731) and older than 75 (late elderly, n = 1,016).
These age categories are used frequently in Japan for
the study of elderly patients and for health care in-
surance purposes [12].Outcome measurements
The primary endpoints were the incidence of IHD and
CVA, specifically fatal and non-fatal myocardial in-
farction and other non-fatal events, including unstable
angina pectoris, angioplasty, stenting, coronary artery
bypass grafting and stroke. Detailed definitions of each
event are shown below. Transient ischemic attacks were
included only if definite focal lesions from the attack were
confirmed by head CT or MRI.
Figure 1 Study profile. “Months” indicates months after March 2005.
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Metabolic factors, such as the levels of plasma lipids,
fasting plasma glucose (FPG), and HbA1C and BP, were
measured at enrollment. The serum LDL-C level was
calculated using the Friedewald equation, except in the
case of a TG level higher than 400 mg/dl, in which case
the LDL-C data were recorded as ‘missing.’ Information
about previous history of IHD and stroke and findings
from a 12-lead ECG were obtained for all patients to as-
sess cardiovascular disease at baseline. The study was
approved by the institutional review boards and by the
safety monitoring board every year. The organizing com-
mittee confirmed all cardiovascular events annually. The
guidelines of the Japan Atherosclerosis Society (2002)
state that the LDL-C level should be less than 120 mg/dl
and that the HDL-C level should be higher than 40 mg/
dl in diabetic individuals; these clinical guidelines were
likely followed by the physicians who were treating these
patients at the time of the study [12].
Statistical methods
The results are presented as the means ± SD. All statis-
tical analyses were performed using JMP software (SAS
Institute, Inc., Cary, NC). The incidences of IHD and
CVA were analyzed in relation to the aforementioned
risk factors. Cox multivariate regression analyses wereused. Because LDL-C/HDL-C interacts strongly with
LDL-C and HDL-C and because non-HDL-C interacts
with triglyceride and LDL-C, we analyzed non-HDL-C
and LDL-C/HDL-C separately. In other words, common
factors (gender, age, duration of diabetes, HbA1C, FPG,
systolic BP (SBP), and diastolic BP (DBP)),TG, LDL-C and
HDL-C were analyzed first. Then, non-HDL-C and com-
mon factors were analyzed. Finally, LDL-C/HDL-C, com-
mon factors and TG were analyzed. Values of P < 0.05
were considered statistically significant.
Definition of major events. Major events such as IHD
and CVA were defined as follows.
1. Definite fatal and nonfatal myocardial infarction
(1 or more of the following criteria must be met):a)Diagnostic ECG at the time of the event.
b)Ischemic cardiac pain (and/or unexplained acute
left ventricular failure) and diagnostic enzyme
levels.
c) Ischemic cardiac pain and/or unexplained acute
left ventricular failure with both equivocal enzyme
levels and equivocal ECG.
d)Diagnostic enzyme levels and equivocal ECG.
e)Angiographic evidence of major artery occlusion
with appropriate ventriculographic wall motion
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no such abnormality.
f ) Postmortem examination.2. Angina pectoris (stable or unstable, both of the
following criteria must be met):a) Ischemic cardiac pain relieved by nitrates.
b) Equivocal ECG.3. Ischemic stroke (1 of the following conditions must
be met):a) Rapid onset of focal neurologic deficit lasting at
least 24 h or leading to death, plus evidence from
neuroimaging (computed tomography or magnetic
resonance imaging) showing cerebral/cerebellar
infarction or no abnormality, or postmortem
examination showing cerebral and/or cerebellar
infarction.
b)Rapid onset of global neurological deficit
(e.g., coma) lasting at least 24 h or leading to
death, plus evidence from neuroimaging showing
infarction, or postmortem examination showing
infarction.
c) Focal neurological deficit (mode of onset
uncertain) lasting at least 24 h or leading to death,
plus evidence from neuroimaging showing
infarction, or postmortem examination showing
infarction.4 Primary intracerebral hemorrhage (1 of the following
conditions must be met):a) Rapid onset of focal neurological deficit lasting at
least 24 h or leading to death, plus neuroimaging
or postmortem examination showing primary
intracerebral and/or cerebellar hemorrhage.
b)Rapid onset of global neurologic deficit (e.g., coma)
lasting at least 24 h or leading to death, plus
evidence from neuroimaging or postmortem
examination showing primary intracerebral and
cerebellar hemorrhage.
c) Focal neurologic deficit (mode of onset uncertain)
lasting at least 24 h or leading to death, plus
evidence from neuroimaging or postmortem
examination showing primary intracerebral and/or
cerebellar hemorrhage.In this study, intracerebral hemorrhage was not in-
cluded in the variable CVA (stroke) because its pa-
thophysiology is reported to be different from other
atherosclerotic diseases, such as stroke and ischemic heart
disease.Results
Subject characteristics
Table 1 presents the following subject characteristics:
plasma lipid levels, including LDL-C, TG, and HDL-C;
other relevant metabolic measures, such as HbA1C level,
FPG level, and SBP and DBP; the duration of diabetes;
and the number of patients who were prescribed medi-
cations for hypertension, dyslipidemia, and diabetes, as
well as the type, upon enrollment. The levels of HbA1C
and HDL-C were not different by age group. Dyslipide-
mia was observed in 79.1% of patients, and anti-hyper-
lipidemic drugs were prescribed for 57.3% of the total
population, of which 83% were HMG-CoA reductase
inhibitors (statins). Statins and insulin were prescribed
with the same frequency for late elderly patients as for
non-elderly patients. Insulin and oral agents for dia-
betes treatment were prescribed for 23.9% and 70.5%
of the late elderly and non-elderly individuals, respectively.
Agents for hypertension and diabetes were prescribed
more often in late elderly patients than in non-elderly pa-
tients. There were also significant differences in several
other factors among the age groups.
IHD and CVA incidence
One hundred fifty-three cases of IHD and 104 CVAs
occurred during the 5.5 years of the study, which repre-
sented incidences of 7.9 and 5.6 per 1,000 patients per
year, respectively. The number of deaths was 59 (3.1/1,000
patient-years) over the 5.5 years (Table 2, Figure 1).
The relationships between IHD or CVA and the back-
ground factors, such as LDL-C level, in each age group
were analyzed by Cox proportional regression analyses
(Table 2, Figure 2).
As described in the methods, non-HDL-C and LDL-C/
HDL-C were analyzed separately from other lipids, such
as LDL-C and triglyceride or HDL-C. However, signifi-
cant factors were the same in total and in each gener-
ation group, although the HR and CI of common factors
(gender, age, duration of diabetes, HbA1C, FPG, systolic
BP (SBP), and diastolic BP (DBP)) were slightly different in
each (data not shown for the HR and CI of common fac-
tors in the analyses of non-HDL-C and LDL-C/HDL-C).
In the total patient population, the levels of HbA1C,
LDL-C, and HDL-C, and the LDL-C/HDL-C ratio were
significantly related to IHD, and only the HDL-C level
was significantly related to a CVA. The HbA1C level,
SBP, and LDL-C levels were significantly correlated with
IHD in patients less than 65 years old, while the vari-
ables female gender, short duration of diabetes and
HDL-C level were correlated with IHD in patients older
than 75. Because the non-HDL-C level and the LDL-C/
HDL-C ratio have been proposed as markers represent-
ing all types of lipids, we included them in a separate
model (excluding LDL-C, triglyceride and HDL-C levels
Table 1 Basic patient profile
n = 4014 Total <65 years 65-74 years ≥75 years P1 Male Female P2
n = 4014 n = 1267 n = 1731 n = 1016 n = 2078 n = 1936
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Gender (% male) 51.2 53.1 49.8 49.9 * 100.0 0 -
Age (yrs,mean/median) 67.9/70 2.0 56.5/58 7.0 70.0/70 2.7 78.8/78 3.5 - 67.0/69 10.0 69.7/70 8.7 **
Duration of DM (months) 177.9 70.0 156.3 64.5 186.1 101.2 190.7 104.3 *** 191.6 108.9 169.8 79.7 **
HbA1C (%) 7.70 0.80 7.74 1.38 7.72 1.18 7.62 1.14 0.17 7.61 1.25 7.79 1.20 **
FPG (mg/dl) 149.8 30.3 157.9 53.2 146.4 45.7 145.4 42.0 ** 150.9 48.8 146.9 44.9 0.17
SBP (mmHg) 137.3 11.7 133.1 17.3 135.3 16.8 146.0 17.5 ** 133.8 17.2 135.9 17.1 *
DBP (mmHg) 74.0 7.3 76.1 11.8 73.5 10.6 72.3 10.7 *** 74.5 11.1 73.3 10.9 *
TG (mg/dl) 138.2 53.8 159.4 156.3 128.5 82.0 128.4 73.0 *** 142.9 126.3 131.3 83.7 0.18
LDL-C (mg/dl) 118.2 21.3 121.6 33.8 117.6 32.1 115.0 29.3 * 115.0 31.8 121.2 31.4 **
HDL-C (mg/dl) 55.8 10.7 54.8 15.6 55.4 15.5 57.7 15.8 0.38 53.42 15.4 56.78 15.7 **
Non-HDL-C (mg/dl) 145.8 23.4 153.2 40.3 143.3 35.5 141.0 31.8 * 143.6 36.9 147.5 35.6 *
LDL-C/HDL-C 2.31 0.74 2.41 1.17 2.31 1.21 2.27 0.88 * 2.33 0.95 2.33 1.28 0.21
Agents for HT (%) 55.5 49.3 56.0 62.3 ** 48.5 62.0 ***
ACEI/ARB 39.7 36.9 40.4 41.9 0.65 35.8 43.4 *
CCB 41.2 32.4 43.7 52.6 0.31 36.0 46.5 *
Others 28.3 22.5 31.8 31.4 0.69 28.9 26.7 0.66
Agents for DL (%) 57.3 63.8 54.8 52.6 ** 52.1 60.1 ***
Strong statins 29.6 31.1 28.3 25.4 0.36 29.7 29.5 0.89
Classical statins 53.3 47.0 58.0 61.6 0.11 51.9 55.0 0.23
Fibrates 8.9 12.0 6.5 6.8 0.13 9.8 7.9 0.18
Others 8.2 9.9 7.2 6.2 0.10 8.6 7.6 0.22
Agents for DM (%) 86.6 76.9 91.6 90.3 ** 85.1 88.6 *
Insulin 23.9 24.4 24.6 21.7 0.42 28.0 32.4 *
Sulfonylurea 49.5 41.5 51.3 53.7 0.21 50.0 48.9 0.29
Others 26.1 34.6 21.4 24.5 0.19 26.0 22.0 *
IHD (/1000 year) 9.68 8.84 10.04 9.87 0.97 10.26 9.47 0.32
CVA (/1000 year) 6.78 4.45 7.44 7.56 0.21 7.02 5.72 0.27
P1: Differences in each factor among ages. P2: Differences in each factor between genders. HbA1C:NGSP, *P < 0.05, **P < 0.01, ***P < 0.001.
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ing LDL-C and HDL-C levels for the LDL-C/HDL-C
ratio). The non-HDL-C level was only correlated with
IHD in patients younger than 65. The LDL-C/HDL-C
ratio was significantly correlated with IHD in patients of
all generations. Age and lower HDL levels were corre-
lated with CVA in patients over 75 years old (Table 2,
Figure 2). Subsequently, we evaluated the relationships
with IHD and CVA according to the quartile categories
for each age group by Kaplan-Meier estimator curves.
The HDL-C level was inversely correlated with IHD and
CVA, particularly in individuals over 75 (Figure 3). The
LDL-C/HDL-C ratio tended to correlate with IHD in all
individuals (Figure 3). For the variable current smokers,
6.8% of the total population of subjects smoked. By age
category, 9.9, 6.7 and 3.8% of patients younger than 65,
patients between 65 and 74, and patients older than 75smoked, respectively. As the duration of diabetes is pretty
long, number of present smokers is not many.
Discussion
Background and discussion points of the study
The numbers of diabetic elderly and their associated net
medical costs have drastically increased in recent dec-
ades. The mean life expectancy is now approximately an
additional 12 and 16 years at age 75 for males and
females in Japan, respectively, although the average life
span is 78.9 and 85.6 years, respectively. Consequently,
the number of late elderly (individuals older than 75)
exceeds 13 million, or 10% of the total Japanese po-
pulation. Diabetes can either develop in the elderly or
continue through old age after an earlier onset, and the
numbers of diabetic elderly are increasing. In Japan,
55% of diabetic individuals were elderly in 2007, and
Table 2 Risk factors for IHD and CVA by Cox multivariate models in each age group (IHD, upper; CVA, lower)
n = 4014 Total (n = 4014) <65 years (n = 1267) 65-74 years (n = 1731) ≥75 years (n = 1016)
IHD Adjusted HR 95% CI P Adjusted HR 95% CI P Adjusted HR 95% CI P Adjusted HR 95% CI P
Gender (women vs. men) 1.103 0.972–1.268 0.197 1.044 0.967–1.073 0.456 1.085 0.978–1.210 0.101 1.132 0.992–1.278 0.019*
Age (per 10 years) 1.013 0.972–1.066 0.328 1.022 0.977–1.079 0.229 1.054 1.002–1.106 0.049* 1.005 0.871–1.139 0.682
Duration of Diabetes (months) 0.995 0.988–1.003 0.053 1.001 0.991–1.008 0.582 0.993 0.985–0.999 0.033* 0.992 0.982–0.999 0.023*
HbA1C (per 1%) 1.171 1.001–1.356 0.047* 1.327 1.025–1.686 0.032* 1.219 0.973–1.487 0.083 0.792 0.479–1.059 0.134
FPG (per 10 mg/dl) 1.004 0.997–1.008 0.432 1.005 0.996–1.013 0.355 1.004 0.997–1.009 0.592 0.999 0.987–1.007 0.761
SBP(per 10 mmHg) 1.008 0.995–1.021 0.186 1.030 1.000–1.055 0.035* 1.014 0.994–1.037 0.175 0.986 0.954–1.014 0.331
DBP(per 10 mmHg) 0.995 0.978–1.015 0.618 0.982 0.948–1.024 0.386 0.980 0.950–1.011 0.206 1.027 0.986–1.073 0.202
TG (quartile) 1.005 0.889–1.166 0.555 1.002 0.996–1.006 0.502 1.108 0.997–1.220 0.065 1.001 0.961–1.046 0.454
LDL-C (quartile) 1.318 1.103–1.585 0.023* 1.571 1.128–2.524 0.016* 1.050 0.932–1.176 0.112 1.156 0.998–1.309 0.054
HDL-C (quartile) 0.751 0.611–0.917 0.005** 0.828 0.646–1.017 0.072 0.987 0.966–1.008 0.204 0.629 0.401–0.856 0.001**
Non-HDL-C (quartile) 1.023 0.981–1.072 0.075 1.025 1.001–1.121 0.044* 1.073 0.982–1.161 0.086 0.941 0.791–1.102 0.621
LDL-C/HDL-C (quartile) 1.583 1.298–1.945 0.001** 2.324 1.516–3.795 0.001** 1.359 1.028–1.824 0.021* 1.407 1.015–2.592 0.029*
CVA Adjusted HR 95% CI P Adjusted HR 95% CI P Adjusted HR 95% CI P Adjusted HR 95% CI P
Gender 1.164 0.985–1.296 0.351 1.014 0.897–1.240 0.655 1.208 0.896–1.526 0.112 0.953 0.912–1.012 0.063
Age 1.015 0.986–1.039 0.282 1.002 0.957–1.076 0.754 1.007 0.916–1.166 0.537 1.103 1.002–1.217 0.048*
Duration of Diabetes 0.998 0.992–1.001 0.206 1.003 0.987–1.017 0.709 0.996 0.989–1.001 0.096 0.999 0.991–1.005 0.818
HbA1C 1.001 0.790–1.214 0.128 1.019 0.691–1.401 0.814 0.997 0.855–1.222 0.569 0.928 0.822–1.010 0.059
FPG 1.005 0.995–1.005 0.803 1.003 0.990–1.018 0.741 1.002 0.995–1.008 0.592 0.998 0.986–1.008 0.711
SBP 1.009 0.993–1.024 0.276 1.024 0.988–1.055 0.185 1.015 0.992–1.037 0.206 0.989 0.957–1.018 0.458
DBP 0.998 0.978–1.020 0.846 0.995 0.958–1.046 0.831 0.981 0.948–1.016 0.278 1.024 0.978–1.074 0.317
TG 1.132 0.908–1.302 0.156 1.053 0.658–1.742 0.833 1.253 0.900–1.780 0.184 1.169 0.746–1.853 0.497
LDL-C 1.009 0.912–1.191 0.675 1.005 1.001–1.100 0.047* 1.015 0.892–1.136 0.714 0.997 0.982–1.012 0.631
HDL-C 0.742 0.596–0.901 0.003** 0.715 0.591–1.191 0.200 0.750 0.494–1.000 0.049* 0.536 0.320–0.851 0.007**
Non-HDL-C 0.981 0.945–1.019 0.206 1.021 1.003–1.141 0.045* 0.942 0.872–1.013 0.172 1.012 0.954–1.077 0.226
LDL-C/HDL-C 1.180 0.951–1.477 0.132 1.271 0.819–2.232 0.263 1.114 0.853–1.582 0.356 1.209 0.803–1.847 0.364
The top panels show the analyses of IHD for subjects aged <65 years (left), 65–74 years (middle) and ≥75 years (right). The lower panels show the incidence of CVA. Bold indicate statistically significant
factors. Hazard ratios and 95% CIs are shown. The ratio of males to females was 1. As LDL-C/HDL-C interacts strongly with LDL-C and HDL-C, and non-HDL-C interacts triglyceride and LDL-C, analysis of
















Figure 2 Risk factors for IHD and CVA by Cox multivariate models in representative age groups (IHD, Left; CVA, Right). The upper panels
show the analyses of IHD for those younger than 65 years old (Left) and CVA for those younger than 65 years old (Right). The lower panels show the
analyses of IHD (Left) and CVA (Right) for those equal to or older than 75 years. HR stands for Hazard Ratio (vertical bar shows 1). Bold characters
indicate statistically significant factors. The right side of each figure shows Hazard Ratios and 95% CIs. Because LDL-C/HDL-C interacts strongly with
LDL-C and HDL-C and because non-HDL-C interacts with triglyceride and LDL-C, we analyzed non-HDL-C and LDL-C/HDL-C separately. In other words,
common factors (gender, age, duration of diabetes, HbA1C, FPG, systolic BP (SBP), and diastolic BP (DBP)), TG, LDL-C and HDL-C were analyzed. Then,
non-HDL-C and common factors were analyzed. Finally, LDL-C/HDL-C, common factors and TG were analyzed.




















Figure 3 The relationships of HDL-C levels and the LDL-C/HDL-C ratio with IHD and CVA in quartile categories for each age group
based on Kaplan-Meier estimator curves. Left: The LDL-C/HDL-C ratio correlates with IHD. The figure shows the data for individuals
aged <65 years. Center: The HDL-C level was inversely correlated with IHD, particularly in individuals aged >75 years. Right: The association
between CVA and HDL-C was more prominent in those individuals aged≥ 75 years. Quartile categories HDL-C: <44.0,
44.1-53.0, 53.1-64.0, >64.1 mg/dl LDL-C/HDL-C: <1.691, 1.692-2.180, 2.181-2.787,
>2.789.
Hayashi et al. Cardiovascular Diabetology 2013, 12:10 Page 8 of 11
http://www.cardiab.com/content/12/1/10approximately 25% were late elderly. These trends are
spreading across the world, mainly in developed countries;
however, the risk factors for IHD or CVA in late elderly
diabetic individuals have not been identified. In the late
elderly, atherosclerotic diseases, such as IHD and CVA,
are a more frequent cause of death than malignancy. In
Canada, diabetic patients are reported to suffer myocardial
infarction approximately 14 years earlier than patients
without diabetes [13]. However, there is little evidence on
the risk and preventive factors for IHD or CVA in the dia-
betic elderly, and there are no reports on the late elderly
[14,15].
Therefore, we organized this study as one of the lar-
gest attempts to examine IHD and CVA in middle-aged
to elderly diabetic individuals. We defined the age cat-
egories as follows: 1) non-elderly: younger than 65, 2)
early elderly: from 65 to 74, and 3) late elderly: equal to
or older than 75. Sixty-five is usually defined as the
threshold for being elderly worldwide [13,16], and 75 is
the beginning of the late elderly age in Japan, as defined
by health insurance and care insurance systems and the
Japan Geriatric Society [12].
The effect of age on IHD and CVA risk factors
One hundred fifty-three cases of IHD and 104 CVAs oc-
curred, which represents 7.8 and 5.7/1,000 people peryear, respectively, over this 5.5-year study, although we
defined stroke strictly and excluded cerebral and sub-
arachnoid hemorrhages from this definition. IHD occurs
2 to 3 times more frequently in diabetic individuals com-
pared to the normal Japanese population, and CVA also
occurs more frequently in diabetic individuals [17]. The
prevalence of IHD and CVA is slightly higher than re-
ported in previous Japanese diabetic studies because we
targeted relatively older diabetic individuals [16,17]. How-
ever, even in diabetic individuals, the combined frequency
of IHD and stroke was slightly lower in the Japanese po-
pulation than among Caucasians [18].
To look for the candidate metabolic markers that may
predict IHD and CVA in various age groups, Cox regres-
sion analyses were performed. The analyses showed that
higher HbA1C and LDL-C levels, SBP and non-HDL-C
were significantly correlated with the occurrence of IHD
in subjects <65 years old, which is similar to previous
reports [14-16]. The ratio of males/females was not sig-
nificantly different between patients < 65, patients be-
tween 65 and 74, and patients ≥75. A relation between
diabetes and ischemic stroke was reported. Patients
(59.8 ± 7.2 y.o.) having a history of coronary heart disease
with diabetes mellitus exhibited a 2.29-fold increased risk
for stroke or TIA during the 4.8- to 8.1-year follow-up
period than patients without diabetes. Impaired fasting
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was not. These results are fairly consistent with those of
the younger patients group (< 65 y.o.) in the present
study [19].
In patients ≥75 y.o., a lower HDL-C level was corre-
lated with IHD and CVA. This is a novel finding of the
present study. Few data are available on the relationship
between elderly type 2 diabetic patients and CVA, par-
ticularly among the late elderly [16-18,20]; therefore, the
finding of the importance of HDL-C in CVA in the late
diabetic elderly may be important. The Kaplan-Meier es-
timator curves, which are shown in Figure 1, support
these findings.
Thus, a lower HDL-C level is an important risk factor
for both IHD and CVA among the late elderly diabetic
patients in this study. Although the protective effects of
higher HDL-C on IHD in the non-elderly are known,
the effects on IHD among late elderly diabetics are not
known [21]. The CVA and IHD incidences in the late
elderly may decrease to the levels found in middle-aged
cohorts if higher HDL-C has protective effects on late
elderly diabetic individuals and if their levels are easily
increased. There are few agents available to increase
HDL-C levels, except exercise, and adequate exercise
or bodily movement may be necessary even in the elderly.
The low HDL-C level may be related to low levels of phys-
ical activity in the elderly, which could influence a CVA in
many ways that are separate from the HDL-C level. Ath-
erosclerosis is an inflammatory disorder, and HDL-C may
preserve endothelial function by increasing endothelial
NO [22].
For LDL-C, three large-scale clinical studies on dysli-
pidemia, which included participants who were up to 75
or 80 years of age, are available [23-25]. Although these
studies reported that the reduction in LDL-C by statins
decreases IHD (including in diabetic people), the effects
were weak in the elderly compared with those in the
non-elderly (e.g., Prosper reported that pravastatin, a
water-soluble statin, induced a 16% decrease in IHD
without any effect on CVA in elderly patients com-
pared to a 21% decrease in non-elderly patients). These
data suggest that simply controlling LDL-C may not pre-
vent IHD or CVA in the elderly. There are also no large
observational studies on the diabetic elderly older than 75
[26,27]. For example, the international FIELD study ana-
lyzed approximately 10,000 patients up to the age of
75 years, with a mean age 63 years [26], and the Swedish
NDR-study analyzed 18,673 patients up to 70 years old,
with a mean age of 60 years [27]. These large observa-
tional studies, analyzing all patients, found LDL-C, non-
HDL-C, HDL-C, triglycerides and ratios of LDL-C/
HDL-C and total-cholesterol/HDL-C to be significant
risk factors for IHD. These data are consistent with
our data on participants younger than 65, although thoseobservational studies did not include patients older than
75. To lower LDL-C levels, 57% of the patients in
our study had already been prescribed anti-dyslipidemic
agents, of which 83% were statins. The average LDL-C
level was 120 mg/dl, which matches the guidelines of the
Japan atherosclerosis society but not that of the American
Heart Association or IDF (100 mg/dl). Although doses
and types of anti-dyslipidemic agents were changed often
during the study, their effects other than LDL reduction
(pleiotropic effects) cannot be evaluated yet.
Our study shows the importance of the LDL-C/HDL-C
ratio as well as HDL-C and LDL-C levels, although the
strength of these effects is different based on age. The
LDL-C/HDL-C ratio was associated with IHD, which may
represent the effect of LDL-C levels in the non-elderly
and HDL-C levels in the elderly [28]. The non-HDL-C
level and the total cholesterol/HDL-C ratio are also pro-
posed markers of atherosclerotic diseases [29,30]. The
non-HDL-C level was associated with IHD only among
those younger than 65, and the total cholesterol/HDL-C
ratio was not significantly associated with IHD (data not
shown). We believe that these data are consistent with
previous data from non-elderly diabetic individuals be-
cause the non-HDL-C level is a reflection of the effect of
triglyceride levels, and hyper-triglyceridemia, complicated
with metabolic syndrome, occurs more often in non-
elderly than in elderly people.
Emerging Risk Factors Collaboration analysis showed
the association of non-HDL-C with IHD and CVA.
However, in this study, it was associated with CVA only
in those younger than 65. The two studies are different
in that 1) our cohort consisted only of diabetic patients;
2) in the Collaboration analysis, the mean age was 56.6
y.o., compared to 67.4 y.o. in our study; and 3) in the
Collaboration analysis, almost all of the patients were
North American or European, whereas our study was
Japanese patients only. In the elderly, triglycerides are
usually lower than in younger individuals, and non-
HDL-C represents triglyceride.
A 1-mg/dl change in HDL-C and/or a 2-mg/dl change
in LDL-C reflect a 2% change in the risk for atheroscler-
otic diseases, and this may be partially consistent within
our diabetic elderly study [31]. The LDL-C/HDL-C ratio
may reflect the direct effects of both LDL-C and HDL-C
levels, which may affect or interact with the progression
of atherosclerosis and thrombosis formation more than
other lipids, such as chylomicrons and chylomicron re-
mnants, which are represented by the non-HDL-C
level or the TC/HDL-C ratio. The fact that elderly in-
dividuals have different risk factors than younger indi-
viduals could be associated with genetic protection from
such events or an accumulation of personal habits that
may provide the elderly with protection. For example,
differences in single nucleotide polymorphisms (SNP)
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subsequently, to the different effects of predictors by
age and should be evaluated in the future [32].
Interestingly, impaired fasting glucose and hyperten-
sion were the strongest predictors of risk for ischemic
stroke or TIA in metabolic syndrome, and HbA1c had
positive associations with glycemia, TG, HDL-C, and
TG/HDL-C but not LDL-C in the study of 118 older
adults aged 65–95 years, of whom less than 6.5% had an
HbA1c of 93% [19,33]. These data is consistent with our
data in diabetic patients younger than 65 [33]. Another
study evaluated the predictors of stroke stratified by age
(at symptom onset: young; <50 years, older; 51–75 years,
and oldest; 75 < years) using data collected over a 4-year
period from 3,053 subjects with stroke. The metabolic
syndrome was the only predictor among the older
patients (OR 1.58) but not in the others. Although most
patients were not diabetic, these types of studies should
be accumulated to evaluate the effect of age on athero-
sclerotic diseases [34].
Conclusions
HbA1C, LDL-C, SBP and non-HDL-C in non-elderly
diabetic individuals, HDL-C in late elderly diabetic indi-
viduals and the LDL-C/HDL-C ratio in all diabetic indi-
viduals were associated with IHD in this population.
HDL-C was also associated with CVA in late elderly dia-
betic individuals. The differences in atherosclerotic risk
by age must be considered in developing individualized
strategies for the prevention of atherosclerotic diseases.
Because this was an observational study, we could not
analyze the detailed effects of treatment, such as the ef-
fect of statins on the risk of IHD or CVA. Although this
study targets Japanese, these new findings on metabolic
markers in the late elderly could provide additional data
for the annotation of cardiovascular risk factors in the
diabetic elderly across the world.
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